2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Biological Therapies, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Gene Therapy, Immunotherapy, Non-Biological Therapies, Chemotherapy, Artificial Intelligence (AI), Deep Learning, Machine Learning, Biological Processes, Pathogenesis, CHIP, Genomics, Immune Mechanism, Metabolism, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Diseases, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Measurable Residual Disease, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult, Elderly, Animal Model
PAPER

3495 Phase separation of NOL9 promotes ribosome biogenesis and doxorubicin resistance in DLBCL

Jia-Ying Liu, Wei Li Zhao III, Certified Doctor2, Li Wang III, MD3
1 Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, No. 197 Ruijin Second Road, Shanghai, China, Shanghai, China
2 Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, No. 197 Ruijin Second Road, Shanghai, China, Shanghai, China
3 Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, No. 197 Ruijin Second Road, Shanghai, China, Shanghai, China

Background: Chemoresistance remains a major obstacle in the treatment of diffuse large B cell lymphoma (DLBCL), particularly in patients with early relapse. The molecular mechanisms driving doxorubicin resistance are incompletely understood. Ribosome biogenesis and translational reprogramming have emerged as key adaptive strategies for tumor cells to withstand chemotherapeutic stress, but the critical regulators in DLBCL remain elusive.

Methods: Integrative transcriptome analysis was performed on 461 newly diagnosed DLBCL patients treated with R CHOP. Single cell RNA seq data from 13 DLBCL patients were analyzed to evaluate NOL9 expression in malignant B cells. In vitro functional assays including CCK 8, flow cytometry, and western blotting were conducted in DLBCL cell lines with NOL9 overexpression or knockdown. Liquid liquid phase separation (LLPS) was characterized by fluorescence imaging, FRAP, and truncation analysis. Polysome profiling and SUnSET assays were performed to assess translation efficiency. Virtual screening and surface plasmon resonance (SPR) were used to identify NOL9 binding compounds. The therapeutic efficacy of rosiglitazone was evaluated in a patient derived xenograft (PDX) model.

Results: NOL9 was identified as a significantly upregulated gene in early relapsed DLBCL patients, and high NOL9 expression correlated with inferior progression free survival. NOL9 overexpression promoted DLBCL proliferation and doxorubicin resistance, while NOL9 knockdown reversed these effects. Mechanistically, NOL9 contains an N terminal intrinsically disordered region (residues 1–122) that mediates LLPS and a middle kinase domain (residues 123–654) responsible for rRNA processing. Both domains cooperatively drive 45S to 28S rRNA maturation, enhance polysome assembly, and increase global translation efficiency. NOL9 upregulated translation of chemoresistance associated genes including CBR1 and USP28, and deletion of either the LLPS domain or the kinase domain abrogated these effects. Virtual screening identified rosiglitazone, an FDA approved antidiabetic drug, as a direct NOL9 binding compound that targets the kinase domain. Rosiglitazone suppressed NOL9 mediated rRNA maturation, reduced CBR1 and USP28 translation, and reversed doxorubicin resistance in vitro. In a NOL9 high PDX model, rosiglitazone combined with doxorubicin significantly suppressed tumor growth, reduced Ki 67, CBR1 and USP28 expression, and increased apoptosis compared with monotherapies.

Conclusion: NOL9 phase separation and kinase activity cooperatively drive ribosome biogenesis and doxorubicin resistance in DLBCL via translational upregulation of CBR1 and USP28. Repurposing rosiglitazone as a NOL9 targeting agent offers a clinically translatable therapeutic strategy for overcoming chemoresistance in NOL9 high DLBCL patients.

Jia-Ying Liu: No relevant conflicts of interest to declare.